These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 27453455

  • 1. Mapping the Beck Depression Inventory to the EQ-5D-3L in Patients with Depressive Disorders.
    Grochtdreis T, Brettschneider C, Hajek A, Schierz K, Hoyer J, Koenig HH.
    J Ment Health Policy Econ; 2016 Jun; 19(2):79-89. PubMed ID: 27453455
    [Abstract] [Full Text] [Related]

  • 2. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B, Lorgelly P.
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [Abstract] [Full Text] [Related]

  • 3. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ, Thompson AJ, Turner AJ, Longworth L, McElhone K, Griffiths CEM, Payne K, BADBIR Study Group.
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [Abstract] [Full Text] [Related]

  • 4. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
    Joyce VR, Sun H, Barnett PG, Bansback N, Griffin SC, Bayoumi AM, Anis AH, Sculpher M, Cameron W, Brown ST, Holodniy M, Owens DK.
    MDM Policy Pract; 2017 Aug; 2(2):2381468317716440. PubMed ID: 30288427
    [Abstract] [Full Text] [Related]

  • 5. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
    Woodcock F, Doble B, CANCER 2015 Consortium.
    Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
    [Abstract] [Full Text] [Related]

  • 6. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK, Tabberer M, Brooks J.
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD, de Hond A, Degeling K, Punt CJA, Koopman M, Uyl-de Groot CA, Versteegh MM, van Oijen MGH.
    Health Qual Life Outcomes; 2020 Jul 20; 18(1):240. PubMed ID: 32690011
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
    Wong CKH, Cheung PWH, Samartzis D, Luk KD, Cheung KMC, Lam CLK, Cheung JPY.
    PLoS One; 2017 Jul 20; 12(4):e0175847. PubMed ID: 28414745
    [Abstract] [Full Text] [Related]

  • 11. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER, van Hazel G, Gibbs P, Hatswell AJ.
    J Med Econ; 2017 Feb 20; 20(2):193-199. PubMed ID: 27676291
    [Abstract] [Full Text] [Related]

  • 12. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A, Green C, Telford C, Zajicek J, Wright D.
    Value Health; 2012 Dec 20; 15(8):1084-91. PubMed ID: 23244811
    [Abstract] [Full Text] [Related]

  • 13. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A, Young CA, Hughes DA.
    Value Health; 2018 Nov 20; 21(11):1322-1329. PubMed ID: 30442280
    [Abstract] [Full Text] [Related]

  • 14. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
    Pullenayegum EM, Chan KK, Xie F.
    Med Decis Making; 2016 Feb 20; 36(2):223-33. PubMed ID: 26139449
    [Abstract] [Full Text] [Related]

  • 15. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I, Morris S, Pashayan N, Matata B, Bashir Z, Maguirre J.
    Health Qual Life Outcomes; 2016 Apr 12; 14():60. PubMed ID: 27072351
    [Abstract] [Full Text] [Related]

  • 16. Can EQ-5D-3L utility values of low back pain patients be validly predicted by the Oswestry Disability Index for use in cost-effectiveness analyses?
    Pellekooren S, Ben ÂJ, Bosmans JE, Ostelo RWJG, van Tulder MW, Maas ET, Huygen FJPM, Oosterhuis T, Apeldoorn AT, van Hooff ML, van Dongen JM.
    Qual Life Res; 2022 Jul 12; 31(7):2153-2165. PubMed ID: 35040002
    [Abstract] [Full Text] [Related]

  • 17. Assessing the external validity of algorithms to estimate EQ-5D-3L from the WOMAC.
    Kiadaliri AA, Englund M.
    Health Qual Life Outcomes; 2016 Oct 04; 14(1):141. PubMed ID: 27716347
    [Abstract] [Full Text] [Related]

  • 18. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D.
    Value Health; 2009 Oct 04; 12(8):1151-7. PubMed ID: 19558372
    [Abstract] [Full Text] [Related]

  • 19. Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly.
    Badia X, Trainer P, Biermasz NR, Tiemensma J, Carreño A, Roset M, Forsythe A, Webb SM.
    J Med Econ; 2018 Apr 04; 21(4):382-389. PubMed ID: 29261359
    [Abstract] [Full Text] [Related]

  • 20. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
    Gray LA, Wailoo AJ, Hernandez Alava M.
    Value Health; 2018 Dec 04; 21(12):1399-1405. PubMed ID: 30502783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.